Xtant Medical (XTNT) Stock Price, News & Analysis

Company Overview

Xtant Medical Holdings, Inc. is a medical technology company focused on developing, manufacturing and marketing surgical products for spinal and orthopedic procedures. The company’s portfolio includes biologic products designed to support bone growth and tissue repair, as well as spinal implants and related surgical instruments.

Its products are used by surgeons and hospitals in procedures involving spinal fusion, reconstruction and other orthopedic applications. Xtant’s biologics portfolio includes allograft and other regenerative solutions, while its hardware offerings include implants and instrumentation intended to support spinal stabilization and correction.

Xtant Medical is headquartered in Belgrade, Montana, and primarily serves the U.S. healthcare market through a network of independent distributors, sales representatives and direct commercial activities. The company was formed through the combination of X-spine Systems and Bacterin International and has continued to expand its offerings in the spine and regenerative medicine markets.

Key Stats

• Today's Range: $0.36 to $0.38
• 50-Day Range: $0.31 to $0.45
• 52-Week Range: $0.27 to $0.95
• Volume: 113,134 shs
• Average Volume: 683,098 shs
• Market Capitalization: $52.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Buy

Xtant Medical Stock Analysis - MarketRank™

Xtant Medical scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Xtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Xtant Medical has a consensus price target of $1.00, representing about 169.5% upside from its current price of $0.37.

Amount of Analyst Coverage

Xtant Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Xtant Medical is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xtant Medical is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xtant Medical has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.21% of the float of Xtant Medical has been sold short.

Short Interest Ratio / Days to Cover

Xtant Medical has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xtant Medical has recently decreased by 85.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xtant Medical does not currently pay a dividend.

Dividend Growth

Xtant Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.00

News Sentiment

Xtant Medical has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Xtant Medical this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for XTNT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xtant Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.70% of the stock of Xtant Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSEAMERICAN:XTNT
• Previous Symbol: AMEX:XTNT
• CIK: 1453593
• Web: xtantmedical.com
• Phone: (406) 388-0480
• Fax: 406-388-1354
• Employees: 151
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Xtant Medical: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +166.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.97 million
• Net Margins: -10.17%
• Pretax Margin: -8.44%
• Return on Equity: -23.45%
• Return on Assets: -12.44%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 2.16
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $133.93 million
• Price / Sales: 0.39
• Cash Flow: $0.08 per share
• Price / Cash Flow: 4.86
• Book Value: $0.36 per share
• Price / Book: 1.04

Miscellaneous

• Outstanding Shares: 140,290,000
• Free Float: 125,277,000
• Market Cap: $52.65 million
• Optionable: Not Optionable
• Beta: -0.15